We are live on ! Find out more
BCM

BlueCrest Capital Management Portfolio holdings

AUM $1.69B
1-Year Est. Return 20.01%
This Fund
S&P 500
This Quarter Est. Return
+3.57%
1 Year Est. Return
+20.01%
3 Year Est. Return
+41.66%
5 Year Est. Return
+41.11%
10 Year Est. Return
+377.48%
AUM
$3.86B
AUM Growth
+$648M
Cap. Flow
+$522M
Cap. Flow %
13.54%
Top 10 Hldgs %
27.7%
Holding
2,121
New
678
Increased
371
Reduced
368
Closed
674

Sector Composition

Rank Sector Weight
1 Technology 10.14%
2 Industrials 8%
3 Healthcare 7.93%
4 Financials 7.7%
5 Energy 4.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CNSL
1351
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
$124K ﹤0.01%
10,009
-50,041
-83% -$583K
MDRX
1352
DELISTED
Veradigm Inc. Common Stock
MDRX
$122K ﹤0.01%
+10,152
New +$125K
ICON
1353
DELISTED
Iconix Brand Group, Inc.
ICON
$122K ﹤0.01%
+20,834
New +$162K
ARC
1354
DELISTED
ARC Document Solutions, Inc.
ARC
$120K ﹤0.01%
+67,678
New +$141K
BRFS
1355
DELISTED
BRF SA
BRFS
$117K ﹤0.01%
+24,925
New +$156K
CPE
1356
DELISTED
Callon Petroleum Company
CPE
$117K ﹤0.01%
1,092
-21,601
-95% -$2.68M
PSEC icon
1357
Prospect Capital
PSEC
$1.07B
$116K ﹤0.01%
17,269
+4,487
+35% +$29.8K
AQN icon
1358
Algonquin Power & Utilities
AQN
$4.49B
$113K ﹤0.01%
11,712
-94
-0.8% -$918
VEON icon
1359
VEON
VEON
$3.62B
$113K ﹤0.01%
+1,891
New +$118K
TXMD icon
1360
TherapeuticsMD
TXMD
$23.5M
$109K ﹤0.01%
+349
New +$107K
MTNB icon
1361
Matinas BioPharma
MTNB
$1.88M
$107K ﹤0.01%
+4,945
New +$143K
MARK
1362
DELISTED
Remark Holdings, Inc.
MARK
$106K ﹤0.01%
2,708
+1,027
+61% +$56.2K
ASXC
1363
DELISTED
Asensus Surgical, Inc.
ASXC
$104K ﹤0.01%
1,838
-5,812
-76% -$212K
RRTS
1364
DELISTED
RoadRunner Transportation Systems, Inc.
RRTS
$104K ﹤0.01%
1,998
+1,530
+327% +$85.2K
GSHTW
1365
DELISTED
Gores Holdings II, Inc. Warrants
GSHTW
$102K ﹤0.01%
+55,020
New +$95.3K
MACK
1366
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$102K ﹤0.01%
+26,297
New +$175K
DRYS
1367
DELISTED
DryShips Inc. Common Stock
DRYS
$102K ﹤0.01%
19,486
-6,315
-24% -$26K
GERN icon
1368
Geron
GERN
$828M
$99K ﹤0.01%
28,861
+6,591
+30% +$25.2K
NBR icon
1369
Nabors Industries
NBR
$1.27B
$99K ﹤0.01%
309
+43
+16% +$15.8K
AGRO icon
1370
Adecoagro
AGRO
$1.44B
$97K ﹤0.01%
12,226
+1,179
+11% +$9.44K
ARAY icon
1371
Accuray
ARAY
$32M
$97K ﹤0.01%
+23,700
New +$110K
CLDX icon
1372
Celldex Therapeutics
CLDX
$2.99B
$97K ﹤0.01%
12,888
+5,265
+69% +$70.4K
CLNE icon
1373
Clean Energy Fuels
CLNE
$427M
$94K ﹤0.01%
25,511
-17,130
-40% -$40.4K
IAG icon
1374
IAMGOLD
IAG
$8.2B
$94K ﹤0.01%
16,232
-523,417
-97% -$3.01M
KND
1375
DELISTED
Kindred Healthcare
KND
$92K ﹤0.01%
10,239
-23,079
-69% -$207K

Similar funds

BlueCrest Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, BlueCrest Capital Management held 2,121 positions worth $3.86B, up 20% from $3.21B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

BlueCrest Capital Management deployed $522M of net new capital in Q2 2018, opening 678 new positions and adding to 371 existing holdings. Its largest new stake was PepsiCo: 255,960 shares worth $27.9M.

By sector, the portfolio is most concentrated in Technology at 10% of assets, up from 6.3% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was Nutrien, an estimated $42.4M trimmed.

  • BlueCrest Capital Management's largest Q2 2018 buy was PepsiCo: 255,960 shares worth $27.9M.
  • BlueCrest Capital Management added most to State Street Financial Select Sector SPDR ETF in Q2 2018, an estimated $91.2M increase.
  • BlueCrest Capital Management's biggest Q2 2018 reduction was Nutrien, cutting an estimated $42.4M.
  • BlueCrest Capital Management fully exited iShares MSCI Emerging Markets ETF in Q2 2018, selling an estimated $19.8M.
  • BlueCrest Capital Management's ten largest holdings make up 28% of its $3.86B portfolio in Q2 2018.
  • BlueCrest Capital Management opened 678 new positions and closed 674 in Q2 2018.
  • BlueCrest Capital Management's portfolio value rose 20% quarter-over-quarter to $3.86B.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.